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Controlled releaseAbstract The objective of the present study is to achieve doxycycline’s maximum therapeutic efﬁ-
cacy. Doxycycline-loaded poly(e-caprolactone) microspheres were prepared by water-in-oil-in-
water (w/o/w) double emulsion solvent evaporation technique with different formulation variables
such as concentrations of drug and polymer. The effects of these variables on surface morphology,
particle size distribution, encapsulation efﬁciency, and in vitro release behavior were examined. To
observe the nature of microspheres, X-ray diffraction studies were carried out. The release data
obtained were determined using various kinetic models and Korsmeyer–Peppas model showed an
acceptable regression value for all compositions. Antibacterial efﬁciency of doxycycline-loaded
poly(e-caprolactone) microspheres were assessed by determining Minimum Inhibition Concentra-
tion (MIC) by standard tube dilution method against four standard pathogenic strains. The
in vitro drug release studies were carried out in phosphate buffer solution (pH 7.2). The results
showed marked retardation of doxycycline release and higher percentage of polymer gave longer
drug release proﬁle. This may deﬁnitely provide a useful controlled-release drug therapy and also
prove to be effective over a long period of time (76 h).
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.
Open access under CC BY-NC-ND license.1. Introduction
Micro-encapsulation (micro-particulate delivery system) was
one of the promising drug delivery system, which delivers the
drugs in a controlled rate over a period of time (Kumar
et al., 2011). The use of controlled-release formulations to deli-
ver anti-bacterials to the site of infection has recently gained
interest. In order to develop a controlled drug delivery system,
the micro-particulate system is developed having a polymer
whether natural or synthetic judiciously combined enclosed
Controlled-release and antibacterial studies 567with a drug in such a way that the active agent is released from
the material in a pre-designed manner. These particulate based
systems for the delivery of drugs are claimed to have enhanced
bioavailability, predictable therapeutic response, greater efﬁ-
cacy and safety and controlled and prolonged drug release pro-
ﬁle with effective treatment at the site of infection at much
smaller doses (Krajewski et al., 2000). They are especially
important in the case of poor drug distribution at the site of
infection due to limited blood circulation to the surrounding
skeletal tissue (Silvio and Bonﬁeld, 1999; Paul and Sharma,
2003).
The theory that polymers could be used as drug carriers to
provide the controlled release of drug(s) is now well estab-
lished. Biodegradable polymers are extensively employed in
controlled-release drug delivery devices because of their abun-
dant source, lack of toxicity, high tissue compatibility and they
are the possible means of delivering drugs by several routes of
administration. Among synthetic materials, biodegradable
polyesters, approved by the Food and Drug Administration
(FDA) for human use, are rapidly gaining recognition.
Poly(e-caprolactone) (PCL) is a well-known hydrophobic, syn-
thetic polyester with excellent tissue compatibility, biodegrad-
ability and existing regulatory approval (Perez et al., 2000;
Lionzo et al., 2007). Degradation of PCL in comparison to
poly (lactide-co-glycolide) (PLGA) and other polymers is slow,
making it suitable for long-term delivery extending over a per-
iod of more than 1 year. This has led to its application in the
preparation of different delivery systems in the form of micro-
spheres, nanoparticles and implants (Kim et al., 2003). Biodeg-
radation of this polymer can be enhanced by copolymers like
PLA (poly (lactic acid)) and PLGA (Schwendeman and Cui,
2001; Sinha et al., 2004; Dongming et al., 2007).
Doxycycline is a FDA approved, potent broad spectrum
antibiotic of tetracycline family used for periodontitis
(Quderaa, 1991; Seymour and Heasman, 1995). It is bacterio-
static, works by interrupting the production of proteins by
bacteria, due to the disruption of transfer RNA and messenger
RNA at the ribosomal sites (Seymour and Heasman, 1995;
Stratton and Lorian, 1996). The Minimal Inhibitory Concen-
tration (MIC) of doxycycline to Porphyromonas gingivalis,
the predominant microorganism found in periodontitis, is
0.125 lg/mL (Larsen, 2002). There are many drawbacks asso-
ciated with the systemic administration of antibiotics used in
the treatment of periodontitis. At the site of periodontal
pocket, there is insufﬁcient antibiotic concentration (Pitcher
et al., 1980; Vanderkerchove et al., 1997) and rapid decline
of plasma antibiotic concentration to sub therapeutic levels
(Govender et al., 2005; Mombelli and Winkelhoff, 1997) forc-
ing repeated dosing for longer periods are some of the major
drawbacks. Therefore the localized drug delivery systems are
needed to be developed that would provide the required con-
centration of doxycycline at periodontal pockets making the
therapy effective with minimum side effects. However, delivery
systems using microspheres are advantageous as they control
the rate of release. Earlier Mundargi et al. (2007) reported
the development and clinical studies on doxycycline-loaded
microspheres based on PLGA and PCL. Also Patel et al.
(2008) reported the microencapsulation of doxycycline into
PLGA by spray drying technique and explained the effect of
polymer molecular weight on process parameters.
Thus the main objective of this study is to achieve doxycy-
cline’s maximum therapeutic efﬁcacy. Doxycycline loadedPCL microspheres were prepared by water-in-oil-in-water (w/
o/w) double emulsion solvent evaporation technique with dif-
ferent formulation variables such as concentrations of drug
and polymer. Also the effect of these variables on microsphere
morphology, particle size distribution, encapsulation efﬁciency
and in vitro release behavior were studied. Antibacterial efﬁ-
ciency of doxycycline loaded PCL microspheres were assessed
by determining MIC by standard tube dilution method against
four standard pathogenic strains (ATCC) in their mid logarith-
mic phase.2. Experimental
2.1. Materials
Doxycycline HCl (DXY) was procured from Aldrich Chemical
Company, Inc. (Milwaukee, WI, USA). Poly(e-caprolactone)
(PCL) (MW=70,000–90,000 by GPC) was purchased from
Aldrich Chemical Company, Inc. (Milwaukee, WI, USA). Poly
vinyl alcohol (PVA) (MW= 1,15,000), and dichloromethane
(DCM) were purchased from S.D. Fine Chemicals (Mumbai,
India). Dialysis membrane-110 was purchased from Himedia
Laboratories Pvt. Ltd. (Mumbai, India).
2.2. Preparation of doxycycline-loaded poly(e-caprolactone)
microspheres
A w/o/w double emulsion solvent evaporation technique with
minor modiﬁcation was adopted to formulate DXY-loaded
PCL microspheres. In this method DXY equivalent to 10%,
20% (w/w) dry weight of PCL was dissolved in 5 mL distilled
water to form DXY aqueous solution; 2 and 4 g of the polymer
were dissolved in 20 mL of DCM, to form polymer solution
that was used as an oil phase; 5 mL of the above-prepared
DXY aqueous solution was added to 20 mL of polymer solu-
tion and emulsiﬁed using a Homogenizer (CHG-15A, Daihan
Scientiﬁc Co. Ltd., Korea) at 30,000 rpm for some time to
form stable w/o emulsion. This stable w/o emulsion was slowly
added to 100 mL aqueous solution of 1 wt.% PVA and emul-
siﬁed using a magnetic stirrer (RQg-128A, Remi Motor Ltd.,
Mumbai, India), at the speed of 550 rpm to form a w/o/w
emulsion under ambient conditions. This was the basis of the
technology, because most of the solvent disappeared by evap-
oration leaving behind thin polymeric coatings on the dry dis-
persed drug in the internal phase of emulsion. Solvent removal
and hardening of the microspheres were done by continuously
stirring the mixture for about 2 h at 25 C. Microspheres were
isolated by ﬁltration and washed with distilled water several
times to the remove residual PVA. The produced microspheres
were dried at ambient temperature (25 C) for 24 h and dried
in a vacuum chamber at 25 C for 12 h to remove the residual
solvent. The details of quantities of drug, polymer and stabi-
lizer used are given in Table 1.
2.3. Determination of drug loading and encapsulation efﬁciency
To determine the DXY content, microspheres were dissolved
in DCM and DXY was extracted with pH 7.2 phosphate
buffer solution (PBS) followed by UV spectrophotometer anal-
ysis. Brieﬂy, 10 mg of each batch of DXY-loaded microspheres
Table 1 Compositions of the microsphere formulation coded (F1–F6).
Formulation PCL (%, w/w) Doxycycline (wt.%) PVA (%, w/w) Dichloromethane (mL) PVA (mL)
F1 10 20 1 20 100
F2 20 20 1 20 100
F3 05 10 1 20 100
F4 05 20 1 20 100
F5 02 10 1 20 100
F6 02 20 1 20 100
568 J.P. Raval et al.was dissolved in DCM and then 10 mL of PBS was added into
this solution to extract DXY several times. The above suspen-
sion was vigorously mixed by vortexing, allowed to get the
clear solution, separated and ﬁltered through Whattman ﬁlter
paper (Sartorius, Germany) to remove the polymeric
debris. The clear solution was analyzed for DXY content by
UV spectrophotometer (SP-3000+, Tokyo, Japan) at the kmax
value of 275 nm. The % drug loading and % encapsulation
efﬁciency of the microspheres were calculated using Eqs. (1)
and (2) (Giovagnoli et al., 2008) and have been compiled in
Table 1:




%Encapsulation efficiency ¼ %Drug loading
%Theoretical loading
 
 100 ð2Þ2.4. Yield of microspheres
Microspheres recovered at the end of preparation were
weighed and the yield was calculated as a percentage of the
total amounts of polymer and drug added during the prepara-
tion of microspheres.
2.5. Scanning electron microscopy (SEM)
Dried microparticles were dispersed in water, and were
dropped onto metal stubs and allowed to dry in air under
ambient conditions. Each sample was coated with gold prior
to examination by SEM (JSM-5410, Jeol, Tokyo, Japan).
2.6. Particle size analysis
Particle size was measured by dynamic laser light scattering
model Halos-BF (Symantec, Germany). Sizes of the com-
pletely dried microspheres of different formulations were mea-
sured by the dry sample technique using a dry sample adapter.
The completely dried particles were placed on the sample tray
with an inbuilt vacuum under a compressed air system, which
was used to suspend the particles. The laser obscuration range
was maintained between 0.1–875 lm. The volume mean diam-
eter (VMD) was recorded. After the measurement of particle
size of each sample, the dry sample adopter was cleaned thor-
oughly to avoid cross contamination. Each batch was analyzed
in triplicate, but average values were considered in data
analysis.2.7. X-ray diffraction (XRD)
Crystalline nature of the pristine DXY and DXY-loaded
microspheres were evaluated by powder XRD technique using
Philips model ‘‘X’’ Pert, diffractometer attached to the digital
graphical assembly and a computer with Cu target X-ray tube-
4 as the Cu a-radiation source in the range of 3 to 136 of
2h.
2.8. In vitro drug release study
In vitro drug release from different formulations was invested
in phosphate buffer solution (PBS) of pH 7.2 (without
enzyme). Microspheres (50 mg) were suspended in 1 mL of
PBS and placed within the dialysis bag. The dialysis bag was
kept in a conical ﬂask containing 100 mL of PBS as the disso-
lution medium and was stirred at 100 rpm using a shaker
(Kuhner, Switzerland) at 37 C. The amount of drug released
was determined by withdrawing 3 mL aliquots at the selected
speciﬁc time intervals. The volume withdrawn was replenished
with an equal volume of fresh and pre-warmed PBS (37 C) to
maintain the constant volume. Samples were analyzed by UV
spectrophotometer (SP-3000+, Tokyo, Japan) at kmax value of
275 nm using PBS as the blank.
2.9. Release kinetics
Data obtained from in vitro analysis were ﬁtted to various
kinetic equations to ﬁnd out the mechanism of drug release
from microspheres. The kinetic equations used were zero-order
equation, ﬁrst-order equation and Higuchi model.
C ¼ k0t ð3Þ
where k0 is zero-order rate constant expressed in units of con-
centration/time and t is the time.
LogC ¼ LogC0  k1t=2:303 ð4Þ
where C0 is the initial concentration of drug and k1 is ﬁrst-
order constant.
Q ¼ kHt1=2 ð5Þ
where kH is the Higuchi constant reﬂecting the design variables
of the system.
The following plots were made: Qt vs t (zero-order kinetic
model), Log(Q0Qt) vs t (ﬁrst-order kinetic model) and Qt
vs square root of t (Higuchi model) (Higuchi, 1963), where
Qt is the total amount of drug released at time t and Q0 is
the initial amount of the drug present in the microspheres.
The rate constants were calculated for the respective models.
Further, to ﬁnd out the mechanism of drug release, the ﬁrst
Figure 1 SEM image of DXY-loaded PCL microspheres.
Figure 2 Particle size distribution of DXY-loaded PCL micro-
spheres. Sample 1 – formulation F1, Sample 2 – formulation F2.
Controlled-release and antibacterial studies 56960% drug release was ﬁtted in Korsmeyer–Peppas (Korsmeyer
et al., 1983) model:
Qt ¼ ktn ð6Þ
where k is the kinetic constant and n is the diffusion exponent,
a measure of the primary mechanism of drug release.
2.10. Antimicrobial studies
The purpose of antibacterial studies was to ﬁnd out drug
release from formulations and its efﬁcacy to inhibit the growth
of microorganisms. The method used for this study was similar
to that used in other dental studies (Ali et al., 2002). The anti-
bacterial potency of the drug needs to be tested as the desired
minimum inhibitory concentration (MIC) has to be achieved.
Thus selected microsphere formulations along with pure drug
were tested for the antibacterial activity as per antimicrobial
assay procedure given in Indian Pharmacopeia. Antibacterial
efﬁciency of DXY-loaded PCL microspheres was assessed by
determining MIC by standard tube dilution method against
four standard pathogenic strains and was evaluated by per-
forming the experiments in triplicate. Pristine DXY at differ-
ent concentrations of 1–100 lg/mL in PBS (pH 7.2) was
tested against organisms such as Escherichia coli (E. coli),
Pseudomonas aeruginosa (P. aeruginosa), Staphylococcus aur-
eus (S. aureus) and Klebsiella pneumoniae (K. pneumoniae).
For Formulation F1 and F2, samples collected from in vitro
release study of DXY-loaded microsphere at different time
intervals (1, 2, 3, 4, 5, 24 h) were also tested against S. aureus
and K. pneumoniae.
3. Results and discussion
3.1. Encapsulation efﬁciency of different formulations
In these studies, encapsulation of DXY with PCL as an excip-
ient was carried out using solvent evaporation method and
various formulations (F1–F6) were prepared. The yield of pro-
duction ranged from 82.90% to 93.55% and the encapsulation
efﬁciencies of DXY-loaded PCL microspheres were found
between 20.09% and 81.38%. When yield of production and
encapsulation efﬁciency of various formulations were evalu-
ated it was found that the drug/polymer ratio does not affect
the production yield but it affects the encapsulation
efﬁciencies.
Comparatively high encapsulation values were obtained
with the microspheres with high drug loading. Also, increase
in the encapsulation efﬁciency was observed with the increase
in the polymer concentration (Table 2).Table 2 Results of production yield, mean particle size encapsulation efﬁciency of different formulations.
Formulation code Production yield (M± SD) (%) Volume mean particle size (M± SD) (lm) Encapsulation eﬃciency (%)
F1 82.90 ± 0.81 76.9 ± 0.43 81.38
F2 93.55 ± 1.53 80.4 ± 0.95 76.42
F3 85.34 ± 0.92 73.9 ± 0.65 61.84
F4 79.42 ± 1.12 68.8 ± 0.72 48.33
F5 83.23 ± 1.34 60.5 ± 0.30 32.00
F6 90.03 ± 1.29 55.9 ± 0.43 20.09
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The SEM of DXY-loaded PCL microspheres of batch F2 is
shown in Fig. 1. It can be seen that microspheres are almost
spherical with smooth surface and no drug crystals were found
on the microsphere surface which might be attributed to the
uniform removal of solvent by evaporation to produce even
polymer distribution.
3.3. Particle size distribution
Results of volume mean particle sizes of different formulations
containing different amounts of DXY and PCL with standard
errors are presented in Table 2, while the size–distribution
curve for typical formulations F1 and F2 is displayed inFigure 3 XRD diffractogram of (a) pristine doxycycline, (b) placFig. 2a and b, respectively. It is obvious that the size distribu-
tion is narrow. As the polymer concentration increases the size
of microsphere increases whereas with the increase in drug
loading, the particle size decreases. When the polymer concen-
tration increases the internal phase becomes more viscous pro-
ducing bigger size particles (Sehra and Dhake, 2005; Joseph
et al., 2002).
3.4. X-ray diffraction
The crystalline natures of pristine DXY and DXY-loaded
microspheres have been evaluated by XRD. XRD diffracto-
grams of (a) pristine DXY, (b) placebo microspheres and (c)
DXY-loaded microspheres (F1–F6) are presented in Fig. 3.
The XRD diffractograms of different formulations do notebo microspheres and (c) (F1–F6) DXY-loaded microspheres.
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a transition from a crystalline to an amorphous state. This
study indicates the dispersion of drugs at a molecular level in
the formulation and also intensity of XRD was dependent
on particle size and its distribution. The XRD intensities
depend on crystal size but in this study for DXY-loaded for-
mulations, the characteristic intensities of DXY have been
overlapped with the noise of the coated PCL indicating molec-
ular level dispersion of DXY in PCL matrix and hence no crys-
tals were found in DXY-loaded matrices.
3.5. In vitro drug release study
In vitro release proﬁles of PCL formulation encapsulating dif-
ferent percentages (10%, 20%) of DXY loading are displayed
in Fig. 4. The release proﬁles indicated that approximately
92% of DXY was released from DXY-loaded PCL micro-
spheres. On the other hand, for all the formulations DXY
microspheres released about 15% of the active ingredient
within 3 h. When hydrophilic drugs like DXY are incorporated
into polymeric microspheres, the drug has a higher afﬁnity
toward the aqueous phase. Thus, the drug is believed to get
released faster initially due to higher solubility of DXY inFigure 4 In vitro release proﬁles of various drug loaded
microspheres’ formulations.
Table 3 Correlation coefﬁcient (r), reaction rate constants (k) and di
of doxycycline from PCL microspheres.
Formulation code Zero order First order
r k0 r k1
A1 0.892 2.038 0.995 0.
A2 0.873 1.804 0.984 0.
A3 0.863 2.303 0.974 0.
A4 0.937 2.339 0.987 0.
A5 0.906 2.821 0.951 0.
A6 0.940 2.731 0.954 0.the dissolution medium giving an initial burst effect. Also, dur-
ing the degradation of PCL microspheres, more acidic groups
are generated and hence, the release of DXY depends on the
different concentrations of PCL. From the Fig. 4, it is assured
that the higher percentage of polymer gave a longer drug
release proﬁle. In this study, DXY release from PCL micro-
spheres prepared by w/o/w double emulsion solvent evapora-
tion technique occurred in 76 h (Fig. 4).
The in vitro release kinetics was carried out to determine the
release mechanism. The release constants were calculated from
the slope of the appropriate plots, and regression coefﬁcient
(R2) by linear regression analysis. The ﬁrst-order release values
for formulations were 0.951–0.995 and 0.863–0.940 for zero
order (Table 3). The release regression values (correlation coef-
ﬁcient values) were best ﬁt with the Higuchi plot (0.986–0.987)
(Fig. 5) rather than ﬁrst and zero orders (Table 3). Thus the
drug release of DXY was proportional to the square root of
time, indicating diffusion controlled-release mechanism for
all the formulations.
In all trials, drug release mechanism was studied by apply-
ing the Korsmeyer–Peppas model and the exponent values
were found to lie between 0.973 and 0.998. Thus the n values
are greater than 0.5 indicating a non-Fickian release (Table 3).ffusion exponent (n) of the model equations applied to the release
Higuchi Korsmeyer–Peppas
r kH r n
011 0.997 11.11 0.998 0.648
008 0.993 9.928 0.992 0.559
013 0.986 12.7 0.973 0.646
014 0.994 12.42 0.990 0.684
022 0.990 15.21 0.977 0.693
02 0.987 14.43 0.980 0.894
Figure 5 Higuchi kinetic release proﬁle of DXY-loaded PCL
microspheres; data for formulations F1–F6.
Table 4 Antibacterial activity of doxycycline against E. coli,
P. aeruginosa, S. aureus and K. pneumoniae.
Concentration
(lg/mL)
Mean zone diameter (cm)
A B C D
100 1.6 1.9 1.9 2.4
75 1.6 2.0 1.8 2.5
50 1.4 1.9 1.3 2.4
25 1.4 1.8 1.1 2.1
10 1.2 1.6 0 1.7
7.5 1.1 1.4 0 1.7
5 1.1 1.2 0 1.2
1 0 1.0 0 0
A – E. coli, B – S. aureus, C – P. aeruginosa, D – K. pneumoniae.
Table 5 Antibacterial activity of in vitro dissolution samples
against S. aureus and K. pneumoniae.
Time (min) Mean zone diameter (cm)
S. aureus K. pneumoniae
D1 D2 D1 D2
0 0 0 0 0
60 1.1 1.1 1.2 1.2
120 1.2 1.1 1.3 1.3
180 1.2 1.1 1.3 1.4
240 1.3 1.3 1.3 1.4
300 1.3 1.4 1.4 1.4
1440 2.3 2.4 2.6 2.7
D1 – 10% PCL+ 20% DXY, D2 – 20% PCL+ 20% DXY.
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Antibacterial efﬁciency of DXY-loaded PCL was assessed by
determining MIC by standard tube pathogenic strains in their
mid logarithmic phase. Observed MICs for K. pneumoniae and
P. aeruginosa were 5 lg/mL and 25 lg/mL, respectively. On
the other hand, S. aureus exhibited susceptibility at lower con-
centration levels (1 lg/mL) while E. coli shows susceptibility at
a slightly higher concentration than that of S. aureus (2.5 lg/
mL).
Also the zone of inhibition was measured (Table 4). In each
case, clear zone of inhibition, with more than 1 cm diameter
was observed. In vitro dissolution samples showed the inhibi-
tion of bacterial growth throughout the test period (Table 5),
conﬁrming the antimicrobial activity of the microspheres. In
vitro release samples obtained from DXY-free microspheres
showed no inhibition of growth of the microorganism. The
zone of inhibition after 12 h for pure drug was more than
the formulations due to the controlled release of drug from
the formulations. DXY was found to be active against K. pneu-
moniae, P. aeruginosa, S. aureus and E. coli.
4. Conclusions
It was demonstrated that concentrations of polymer and drug
affect the particle size, encapsulation efﬁciency and drug
release. Biodegradable PCL microspheres with high loading
DXY (81%) were successfully prepared using the w/o/w dou-
ble emulsion solvent evaporation technique as described here.Comparing all the formulations developed, F2 showed opti-
mum release characteristics and is the most promising for
improved DXY release. The release rate of drug from the
microspheres could be properly controlled for 76 h. It is
assured that a higher percentage of polymer gives longer drug
release proﬁle. Appropriate variation in the proportions of
drug and coating polymer can lead to a product with
the desired controlled-release features. Antimicrobial studies
showed that the released drug from the formulations was
effectively inhibiting the growth of microorganisms with the
MIC of <1 lg/mL which proves the potential of
formulations for the treatment of infections caused by such
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